Nonviral and viral gene transfer into different subsets of human dendritic cells yield comparable efficiency of transfection

被引:34
作者
Lundqvist, A
Noffz, G
Pavlenko, M
Sæboe-Larssen, S
Fong, T
Maitland, N
Pisa, P
机构
[1] Karolinska Hosp, Canc Ctr Karolinska, Radiumhemmet, Dept Pathol & Oncol, S-17177 Stockholm, Sweden
[2] Univ Oslo, Norwegian Radium Hosp, Dept Immunol, Canc Res Inst,Sect Immunotherapy, Oslo, Norway
[3] Chiron Corp, Canc Therapeut Grp, Emeryville, CA 94608 USA
[4] Univ York, Canc Res Unit, York YO1 5DD, N Yorkshire, England
关键词
dendritic cells; electroporation; gene transfer; transfection efficiency;
D O I
10.1097/00002371-200211000-00001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Among the many promising cancer immunotherapeutic strategies, dendritic cells (DC) have become of particular interest. This study aims to optimize a clinical grade protocol for culture and transfection of human DC. Monocytes and CD34(+) hematopoietic stem cells (HSC) from same donor were differentiated under serum-free conditions and analyzed for their susceptibility to several recently described nonviral transfection methods as compared with established virally mediated gene transfer. Nonviral gene transfer methods studied were square-wave electroporation, lipofection, and particle-mediated transfer of plasmid DNA or in vitro transcribed mRNA. We conclude that DNA is not suitable for transduction of DC using nonviral methods. In contrast, mRNA and square-wave electroporation reproducibly yields 60% and 50% transfected monocyte- and CD34(+)-derived DC, respectively, measured at protein level, without affecting the cell viability. Thus, the transfection efficiency of this method is comparable with the 40-90% transgene expression obtained using retroviral (RV) or adenoviral (AdV) vectors in CD34(+)- and monocyte-derived DC, respectively. In monocyte-derived DC, however, the amount of protein expressed per-cell basis was higher after AdV (MOI = 1000) compared with mRNA electroporation-mediated transfer. This is the first study directly demonstrating side-by-side that mRNA electroporation into DC of different origin indeed results in a comparable number of transduced cells as when using virus-mediated gene transfer.
引用
收藏
页码:445 / 454
页数:10
相关论文
共 53 条
  • [11] Monocyte-derived CD1a+ and CD1a- dendritic cell subsets differ in their cytokine production profiles, susceptibilities to transfection, and capacities to direct Th cell differentiation
    Chang, CCJ
    Wright, A
    Punnonen, J
    [J]. JOURNAL OF IMMUNOLOGY, 2000, 165 (07) : 3584 - 3591
  • [12] Effective repeat administration with adenovirus vectors to the muscle
    Chen, P
    Kovesdi, I
    Bruder, TJ
    [J]. GENE THERAPY, 2000, 7 (07) : 587 - 595
  • [13] Immune responses to adenovirus and adeno-associated virus in humans
    Chirmule, N
    Propert, KJ
    Magosin, SA
    Qian, Y
    Qian, R
    Wilson, JM
    [J]. GENE THERAPY, 1999, 6 (09) : 1574 - 1583
  • [14] DNA-based immunization by in vivo transfection of dendritic cells
    Condon, C
    Watkins, SC
    Celluzzi, CM
    Thompson, K
    Falo, LD
    [J]. NATURE MEDICINE, 1996, 2 (10) : 1122 - 1128
  • [15] Human PBMC-derived dendritic cells transduced with an adenovirus vector induce cytotoxic T-lymphocyte responses against a vector-encoded antigen in vitro
    Diao, J
    Smythe, JA
    Smyth, C
    Rowe, PB
    Alexander, IE
    [J]. GENE THERAPY, 1999, 6 (05) : 845 - 853
  • [16] High efficiency adenovirus-mediated gene transfer to human dendritic cells
    Dietz, AB
    Vuk-Pavlovic, S
    [J]. BLOOD, 1998, 91 (02) : 392 - 398
  • [17] Engelmayer J, 1999, J IMMUNOL, V163, P6762
  • [18] Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo
    Fields, RC
    Shimizu, K
    Mulé, JJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (16) : 9482 - 9487
  • [19] Dendritic cells in cancer immunotherapy
    Fong, L
    Engleman, EG
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, 2000, 18 : 245 - 273
  • [20] Fong TC, 2000, CRIT REV THER DRUG, V17, P1